Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)

BACKGROUND: Dacomitinib is the second‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) for mutant non–small cell lung cancer (NSCLC). EGFR‐TKIs are often re‐administered in Japan after the disease progression prior EGFR‐TKI. There is little evidence of dacomitinib i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Hisashi, Sakamoto, Hiroaki, Akita, Takahiro, Ohyanagi, Fumiyoshi, Kawashima, Yosuke, Tambo, Yuichi, Tanimoto, Azusa, Horiike, Atsushi, Miyauchi, Eisaku, Tsuchiya‐Kawano, Yuko, Yanagitani, Noriko, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108073/
https://www.ncbi.nlm.nih.gov/pubmed/35415873
http://dx.doi.org/10.1111/1759-7714.14415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108073/
https://www.ncbi.nlm.nih.gov/pubmed/35415873
http://dx.doi.org/10.1111/1759-7714.14415

Ejemplares similares